Hypoglycemic Potential of Current and Emerging Pharmacotherapies in Type 2 Diabetes Mellitus
- 1 July 2012
- journal article
- Published by Taylor & Francis Ltd in Postgraduate Medicine
- Vol. 124 (4), 74-83
- https://doi.org/10.3810/pgm.2012.07.2570
Abstract
Intensive glycemic control can reduce the risk of microvascular complications in patients with type 2 diabetes mellitus (T2DM). However, hypoglycemia induced by diabetes medications is recognized as a major limiting factor in the attainment of glycemic goals. Mild hypoglycemia is relatively common in patients with T2DM, and the prevalence of severe hypoglycemia increases with insulin treatment and can approach the prevalence seen in patients with type 1 diabetes. Mild hypoglycemia and the fear of hypoglycemia can have a substantial impact on the physical, mental, social, and economic well-being of patients with T2DM. Severe hypoglycemia is more serious and may be associated with an increased risk of dementia, cardiovascular events, and death. Insulin and insulin secretagogue therapies (eg, sulfonylureas and meglitinides) are the major causes of hypoglycemia in patients with T2DM. Other diabetes drugs, such as metformin, when used as monotherapy, have a low risk of hypoglycemia. Emerging experimental therapies, such as activators of the free fatty acid receptor 1, G protein-coupled receptor 119 agonists, glucokinase activators, inhibitors of 11β-hydroxysteroid dehydrogenase type 1, and sodium-glucose co-transporter 2 inhibitors, some of which have mechanisms of action consistent with a potential low risk of hypoglycemia, may help patients with T2DM achieve improved glycemic control.Keywords
This publication has 64 references indexed in Scilit:
- The Barrier of Hypoglycemia in DiabetesDiabetes, 2008
- Iatrogenic Inpatient Hypoglycemia: Risk Factors, Treatment, and PreventionDiabetes Spectrum, 2008
- Hypoglycaemia in Type 2 diabetesDiabetic Medicine, 2008
- Insulin-Related Knowledge Among Health Care Professionals in Internal MedicineDiabetes Spectrum, 2007
- Cerebral Blood Flow Velocity and Periventricular White Matter Hyperintensities in Type 2 DiabetesDiabetes Care, 2006
- Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetesJournal of the American College of Cardiology, 2003
- Diabetes and AtherosclerosisJama-Journal Of The American Medical Association, 2002
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998